NinaMED

Executive Summary

NinaMED is a medical device company focused on developing the Nina system, a novel treatment for overactive bladder (OAB). In May 2026, the company, in partnership with EBT Medical, announced a $13.75 million financing round to advance the licensed Nina system. This funding is expected to support clinical development, regulatory submissions, and initial commercialization efforts. The Nina system represents a potential new approach to manage OAB, a condition affecting millions worldwide, and could offer a non-invasive or minimally invasive alternative to existing therapies. With this capital infusion, NinaMED is positioned to progress through key milestones, though the company remains in early stages with limited public information. The success of the Nina system depends on clinical outcomes, regulatory approvals, and market adoption. Overall, NinaMED has a promising yet risky profile.

Upcoming Catalysts (preview)

• Q3 2026FDA Investigational Device Exemption (IDE) approval or pivotal trial initiation70% success
• Q4 2026Interim clinical data readout from ongoing studies60% success
• Q1 2027Additional financing or partnership announcement80% success